Systimmune Inc.

This early-phase trial is testing a new drug called BL-M11D1 in 120 adults with acute myeloid leukemia that has come back or not responded to standard treatments. The drug is designed to target and deliver a toxin directly to leukemia cells. The main goals are to check safety, fi…

This early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delive…

This early-phase study tests a new drug called BL-M05D1 in people with advanced or metastatic solid tumors (like stomach, pancreatic, or bile duct cancer) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug c…

This Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior trea…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…